Angels Investments Cuts Protalix Stake to 3.8%

TL;DR

**Angels Investments just cut their Protalix stake to 3.8%, signaling a potential bearish shift.**

AI Summary

Angels Investments in Hi Tech Ltd, an Israeli entity, filed an amended Schedule 13G/A on January 2, 2024, indicating a change in their beneficial ownership of Protalix BioTherapeutics, Inc. common stock. As of December 31, 2023, they reported shared voting and dispositive power over 2,208,913 shares, representing 3.8% of the company's outstanding stock. This matters to investors because it shows a significant institutional holder has reduced their stake below the 5% threshold, potentially signaling a shift in their investment strategy or outlook on Protalix BioTherapeutics.

Why It Matters

This filing shows a significant institutional investor, Angels Investments in Hi Tech Ltd, has reduced its stake in Protalix BioTherapeutics, Inc. below the 5% reporting threshold, which could be interpreted as a loss of confidence or a portfolio rebalancing.

Risk Assessment

Risk Level: medium — A notable institutional investor reducing their stake could indicate a perceived increase in risk or a less favorable outlook for the company.

Analyst Insight

A smart investor would monitor Protalix BioTherapeutics, Inc.'s stock performance and news closely, as a reduction in a significant institutional stake could signal underlying concerns or a shift in market sentiment, prompting a re-evaluation of their own position.

Key Numbers

• 2,208,913 — Shares Beneficially Owned (Represents the number of Protalix BioTherapeutics, Inc. common shares Angels Investments in Hi Tech Ltd has shared voting and dispositive power over as of December 31, 2023.)
• 3.8% — Percentage of Class (This percentage indicates Angels Investments in Hi Tech Ltd's current ownership stake in Protalix BioTherapeutics, Inc., which is below the 5% threshold typically requiring more detailed reporting.)

Key Players & Entities

• Angels Investments in Hi Tech Ltd (company) — reporting person, beneficial owner of Protalix BioTherapeutics, Inc. shares
• Protalix BioTherapeutics, Inc. (company) — subject company, issuer of the common stock
• Marius Nacht (person) — filed by, associated with the reporting entity
• 2,208,913 shares (dollar_amount) — number of shares beneficially owned with shared voting power
• 3.8% (dollar_amount) — percentage of Protalix BioTherapeutics, Inc. common stock beneficially owned
• December 31, 2023 (date) — date of event requiring the filing
• January 2, 2024 (date) — filing date of the SC 13G/A

Forward-Looking Statements

• Protalix BioTherapeutics, Inc. stock price may experience short-term volatility due to the reported reduction in institutional ownership. (Protalix BioTherapeutics, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, Par Value $0.001 per Share (Title of Class of Securitie

Filing Documents

• zk2430712.htm (SC 13G/A) — 94KB
• 0001178913-24-000004.txt ( ) — 95KB

(a)

Item 1(a) Name of Issuer Protalix BioTherapeutics, Inc. (the "Issuer").

(b)

Item 1(b) Address of Issuer's Principal Executive Offices 2 Snunit Street, Science Park, POB 455, Carmiel 2161401, Israel

(a)-(b) Name of Person Filing; Address of Principal Business Office or, if none, Residence

Item 2(a)-(b) Name of Person Filing; Address of Principal Business Office or, if none, Residence 1. Angels Investments in Hi Tech Ltd. ("Angels") c/o Marius Nacht, 42 Brandeis St. Tel Aviv 6200157, Israel 2. Marius Nacht, 42 Brandeis St. Tel Aviv 6200157, Israel The foregoing persons are hereinafter collectively referred to as the "Reporting Persons".

(c)

Item 2(c) Citizenship Angels is an Israeli company; and Marius Nacht is an Israeli citizen.

(d)

Item 2(d) Title of Class of Securities Common Stock, par value $0.001 per share

(e)

Item 2(e) CUSIP Number 74365A309 Item 3 If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: Not applicable. Item 4 Angels Investments in Hi Tech Ltd. (a) Amount beneficially owned : 2,208,913 shares of Common Stock. The number of shares of Common Stock set forth above consists of 237,012 shares of Common Stock and 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023 All share percentage calculation are based on (i) 72,952,124 shares of Common Stock outstanding as of November 1, 2023, as reported by the Issuer to the SEC on Form 10-Q on November 6, 2023 and (ii) 1,971,901 shares of Common Stock of the Issuer that the Reporting Person has the right to acquire pursuant to warrants that are exercisable within 60 days of December 31, 2023, which are treated as issued and outstanding solely for the purpose of computing the percentage ownership of the Reporting Person pursuant to Rule 13d-3(d)(1)(i) under the Act. (b) Percent of Class : 2.9% (c) Number of shares as to which the person has : (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or to direct the vote: 2,208,913 shares of Common Stock (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 2,208,913 shares of Common Stock Page 4 of 7 Pages Marius Nacht (a) Amount beneficially owned : 2,208,913 shares of Common Stock. Marius Nacht is the sole shareholder and director of Angels. By reason of Mr. Nachts control over Angels, By virtue of such relationship, Marius Nacht may be deemed to have shared voting and investment power with respect to the shares of Common Stock of the Issuer held by Angels. The number of shares of Common Stock set forth above consists of 237,012 shares of Common Stock and 1

View Full Filing

View this SC 13G/A filing on SEC EDGAR